| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 2883 | 2019 |
| Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 622 | 2020 |
| Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial TE Hutson, V Lesovoy, S Al-Shukri, VP Stus, ON Lipatov, AH Bair, ... The Lancet Oncology 14 (13), 1287-1294, 2013 | 451 | 2013 |
| RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem … J Motsch, C Murta de Oliveira, V Stus, I Köksal, O Lyulko, HW Boucher, ... Clinical Infectious Diseases 70 (9), 1799-1808, 2020 | 323 | 2020 |
| Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I … KS Kaye, T Bhowmick, S Metallidis, SC Bleasdale, OS Sagan, V Stus, ... Jama 319 (8), 788-799, 2018 | 310 | 2018 |
| Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 … KS Kaye, LB Rice, AL Dane, V Stus, O Sagan, E Fedosiuk, AF Das, ... Clinical Infectious Diseases 69 (12), 2045-2056, 2019 | 134 | 2019 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 131 | 2023 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor … BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019 | 128 | 2019 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of … BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ... Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021 | 126 | 2021 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. ER Plimack, BI Rini, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 38 (15_suppl), 5001-5001, 2020 | 77 | 2020 |
| Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial TE Hutson, S Al-Shukri, VP Stus, ON Lipatov, Y Shparyk, AH Bair, ... Clinical genitourinary cancer 15 (1), 72-76, 2017 | 64 | 2017 |
| Екологія довкілля та безпека життєдіяльності населення у промислових регіонах України АМ Сердюк, ВП Стусь, ВІ Ляшенко Дніпропетровськ: Пороги, 2011 | 50 | 2011 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 41 (17_suppl), LBA4501-LBA4501, 2023 | 42 | 2023 |
| Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial L Albiges, H Gurney, V Atduev, C Suarez, MA Climent, D Pook, ... The Lancet Oncology 24 (8), 881-891, 2023 | 39 | 2023 |
| Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma J Bedke, BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, ... European Urology 82 (4), 427-439, 2022 | 39 | 2022 |
| Охрана окружающей среды и человека в уранодобывающих регионах ВИ Ляшенко, ОВ Люлько, ВП Стусь Новини науки Придніпров’я. Серія: Інженерні науки, 37-46, 2003 | 30 | 2003 |
| Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC). TE Hutson, J Gallardo, V Lesovoy, S Al-Shukri, V Stus, AH Bair, ... Journal of clinical Oncology 31 (6_suppl), LBA348-LBA348, 2013 | 29 | 2013 |
| RESTORE-IMI 1: a multicenter, randomized, double-blind, comparator-controlled trial comparing the efficacy and safety of imipenem/relebactam versus colistin plus imipenem in … J Motsch, C De Oliveira, V Stus, I Koksal, O Lyulko, H Boucher Madrid: European Congress of Clinical Microbiology & Infectious Diseases, 2018 | 28 | 2018 |
| Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis (AP): results from a multi-center, randomized … KS Kaye, LB Rice, A Dane, V Stus, O Sagan, E Fedosiuk, A Das, ... Open Forum Infectious Diseases 4 (suppl_1), S528-S528, 2017 | 23 | 2017 |
| Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study ER Plimack, T Powles, V Stus, R Gafanov, D Nosov, T Waddell, ... European Urology 84 (5), 449-454, 2023 | 22 | 2023 |
Поліон М.Ю. , Polion M.Y., Polion M.,...Dnipro State Medical University在 dmu.edu.ua 的电子邮件经过验证
